磷酸二酯酶5抑制剂与肿瘤发病关联研究的新进展

Progress in research of association between phosphodiesterase 5 inhibitors and cancer incidence

伴随磷酸二酯酶5抑制剂(PDE5Is)用药数量的逐年增加,大量人群研究提示PDE5Is与特定肿瘤发病风险存在潜在关联。本文针对PDE5Is与各种肿瘤发病风险关联及机制研究进行系统梳理,已有研究进行Meta分析,结果显示,使用PDE5Is可能与黑色素瘤(RR=1.11,95%CI:1.02~1.22)、基底细胞癌(RR=1.16,95%CI:1.13~1.20)发病风险增加相关,鳞状细胞癌结果尚不一致,与前列腺癌(OR=0.71,95%CI:0.40~1.29)无统计学关联,对结直肠癌(RR=0.85,95%CI:0.76~0.95)可能具有预防作用。建议未来针对现有研究的经验及不足开展进一步深入探索。

With the increased use of phosphodiesterase 5 inhibitors(PDE5Is)over the past years,several population based studies have suggested a potential association between PDE5Is and the risk for specific cancers.This paper systematically summarizes the current status of relatedstudies.Meta-analyses on current research indicated that the use of PDE5Is might be associated with the increased risk for melanoma(RR=1.11,95%CI:1.02-1.22)and basal cell carcinoma(RR=1.16,95%CI:1.13-1.20),but not for prostate cancer(OR=0.71,95%CI:0.40-1.29),and might have chemoprophylaxis effect on colorectal cancer(RR=0.85,95%CI:0.76-0.95).However,results of squamous cell carcinoma were still inconsistent.Further exploration based on the experience and limitations of current research is suggested.